If you have been reading about mass spectrometry and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-01-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV; not a natural hormone. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Naming conventions differ across vendors and papers. |
| CAS Registry Number | 1401708-83-6 | Listed in some chemical databases; verify against primary sources. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Solubility | Soluble in DMSO; limited in water | Organic stock solutions are common in laboratory settings. |
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
To have a better chance of detecting Type III artificial sources, Calissendorff suggests taking several photographs in a row, fast enough to fix the movement of turbulence in the atmosphere, applying different photometric filters and looking for dark areas (the case of a Dyson sphere being assembled by a Type II civilization), or analyzing the infrared spectrum of galaxies. A much larger sample of objects should be studied.
The yeast has a negative effect on the bacteria that normally produce antibiotics to kill the parasite, so may affect the ants' health by allowing the parasite to spread. A different yeast species is grown by fungus-growing ants of the genus Cyphomyrmex. Certain strains of some species of yeasts produce proteins called yeast killer toxins that allow them to eliminate competing strains. (See main article on killer yeast.) This can cause problems for winemaking but could potentially also be used to advantage by using killer toxin-producing strains to make the wine. Yeast killer toxins may also have medical applications in treating yeast infections (see "Pathogenic yeasts" section below). Marine yeasts, defined as the yeasts that are isolated from marine environments, are able to grow better on a medium prepared using seawater rather than freshwater. The first marine yeasts were isolated by Bernhard Fischer in 1894 from the Atlantic Ocean, and those were identified as Torula sp. and Mycoderma sp. Following this discovery, various other marine yeasts have been isolated from around the world from different sources, including seawater, seaweeds, marine fish and mammals. Among these isolates, some marine yeasts originated from terrestrial habitats (grouped as facultative marine yeast), which were brought to and survived in marine environments. The other marine yeasts were grouped as obligate or indigenous marine yeasts, which are confined to marine habitats. However, no sufficient evidence has been found to explain the indispensability of seawater for obligate marine yeasts.
m-Xylene, p-Xylene, o-Xylene, ethyl acetate, ethanol, methanol, pyridine, acetylpyrazine, 2,3,5-trimethylpyrazine, octamethylcyclotetrasiloxane, catechol, m-Cresol, and o-Cresol have been found in the e-cigarette vapor. A 2017 study found that "The maximum detected concentrations of benzene, methanol, and ethanol in the samples were higher than their authorized maximum limits as residual solvents in pharmaceutical products." Trace amounts of toluene and xylene have been found in the e-cigarette vapor. Polycyclic aromatic hydrocarbons (PAHs), aldehydes, volatile organic compounds (VOCs), phenolic compounds, flavors, tobacco alkaloids, o-Methyl benzaldehyde, 1-Methyl phenanthrene, anthracene, phenanthrene, pyrene, and cresol have been found in the e-cigarette vapor. While the cause of these differing concentrations of minor tobacco alkaloids is unknown, Lisko and colleagues (2015) speculated potential reasons may derive from the e-liquid extraction process (i.e., purification and manufacturing) used to obtain nicotine from tobacco, as well as poor quality control of e-liquid products. In some studies, small quantities of VOCs including styrene have been found in the e-cigarette vapor. A 2014 study found the amounts of PAHs were above specified safe exposure limits. Low levels of isoprene, acetic acid, 2-butanodione, acetone, propanol, and diacetin, and traces of apple oil (3-methylbutyl-3-methylbutanoate) have been found in the e-cigarette vapor. Flavoring substances from roasted coffee beans have been found in the e-cigarette vapor.
=== Future developments === Several medications designed to address the root cause are under development, including gene therapy and antisense drugs. Other medications used include corticosteroids to slow muscle degeneration. Physical therapy, orthopedic braces, and corrective surgery may help with some symptoms while assisted ventilation may be required in those with weakness of breathing muscles. Outcomes depend on the specific type of disorder. In February 2024, the results of a 48-week trial with Vamorolone in patients with Duchenne muscular dystrophy (The VISION-DMD study) were published. Patients showed improvements in motor outcomes seen with 6 mg/kg/d of Vamorolone at 24 weeks of treatment and were maintained for 48 weeks of treatment. As well, bone morbidities of prednisone (stunting of growth and declines in serum bone biomarkers) were reversed when treatment transitioned to Vamorolone.
Sources: en.wikipedia.org
These "masculinized" genitalia are often found alongside other traits, such as female-dominated social groups, reduced sexual dimorphism that makes females the same size as males, and even ratios of sexes in adult populations. This phenomenon that has been dubbed the "lemur syndrome". A 2014 study of Eulemur masculinization proposed that behavioral and morphological masculinization in female Lemuriformes is an ancestral trait that likely emerged after their split from Lorisiformes.
For example, phenanthrene has two Clar structures: one with just one aromatic sextet (the middle ring), and the other with two (the first and third rings). The latter case is therefore the more characteristic electronic nature of the two. Therefore, in this molecule the outer rings have greater aromatic character whereas the central ring is less aromatic and therefore more reactive. In contrast, in anthracene the resonance structures have one sextet each, which can be at any of the three rings, and the aromaticity spreads out more evenly across the whole molecule. This difference in number of sextets is reflected in the differing ultraviolet–visible spectra of these two isomers, as higher Clar pi-sextets are associated with larger HOMO–LUMO gaps; the highest-wavelength absorbance of phenanthrene is at 293 nm, while anthracene is at 374 nm. Three Clar structures with two sextets each are present in the four-ring chrysene structure: one having sextets in the first and third rings, one in the second and fourth rings, and one in the first and fourth rings. Superposition of these structures reveals that the aromaticity in the outer rings is greater (each has a sextet in two of the three Clar structures) compared to the inner rings (each has a sextet in only one of the three).
On 16 February, the Syrian government forces intensified their drone attacks, which resulted in the death of one person and five injuries in the Mansoura-Walgha village area. A car exploded in Al-Qurayya, injuring two people, a Syrian source stated that the car was carrying weapons and ammunition. On 17 February, the emir of Dar Ara, Abu Yahya Hassan Al-Atrash, defected to the Syrian government forces, arriving at Daraa Governorate from Suwayda, sources stated that Hikmat al-Hijri does not want other leaders in Suwayda, except him. On 19 February, an unknown group kidnapped Yahya al-Hajjar, the former leader of Men of Dignity, on his farm in rural Suwayda, the Men of Dignity declared a state of maximum alert immediately after the kidnapping, when al-Hajjar was released, he was taken to the guesthouse of the Men of Dignity leader, Sheikh Mazid Khaddaj. On 22 February, the Syrian government forces launched attacks toward Al-Majdal, the National Guard responded to the attacks. On 24 February, an armed group from the village of Labin attacked the Internal Security Forces after an attempt to free one of its members who had been arrested for theft. At the Suwayda headquarters of the Criminal Security branch, the Rapid Intervention Battalion, led by Ruad Abdul Khaliq, clashed with a group from the Abu Sarhan family.
Sources: en.wikipedia.org
=== Pharmacogenetics === Since amitriptyline is primarily metabolized by CYP2D6 and CYP2C19, genetic variations within the genes coding for these enzymes can affect its metabolism, leading to changes in the concentrations of the drug in the body. Increased concentrations of amitriptyline may increase the risk for side effects, including anticholinergic and nervous system adverse effects, while decreased concentrations may reduce the drug's efficacy. Individuals can be categorized into different types of CYP2D6 or CYP2C19 metabolizers depending on which genetic variations they carry. These metabolizer types include poor, intermediate, extensive, and ultrarapid metabolizers. Most individuals (about 77–92%) are extensive metabolizers, and have "normal" metabolism of amitriptyline. Poor and intermediate metabolizers have reduced metabolism of the drug as compared to extensive metabolizers; patients with these metabolizer types may have an increased probability of experiencing side effects. Ultrarapid metabolizers use amitriptyline much faster than extensive metabolizers; patients with this metabolizer type may have a greater chance of experiencing pharmacological failure. The Clinical Pharmacogenetics Implementation Consortium recommends avoiding amitriptyline in patients who are CYP2D6 ultrarapid or poor metabolizers, due to the risk of a lack of efficacy and side effects, respectively. The consortium also recommends considering an alternative drug not metabolized by CYP2C19 in patients who are CYP2C19 ultrarapid metabolizers.
=== Peptide masking === Similar to the idea of pro-drugs, another way of masking the drugs chemical composition is by masking a peptide's characteristics by combining with other molecular groups that are more likely to pass through the blood–brain barrier. An example of this is using a cholesteryl molecule instead of cholesterol that serves to conceal the water soluble characteristics of the drug. This type of masking as well as aiding in traversing the blood–brain barrier. It also can work to mask the drug peptide from peptide-degrading enzymes in the brain Also a "targetor" molecule could be attached to the drug that helps it pass through the barrier and then once inside the brain, is degraded in such a way that the drug cannot pass back through the brain. Once the drug cannot pass back through the barrier the drug can be concentrated and made effective for therapeutic use. However drawbacks to this exist as well. Once the drug is in the brain there is a point where it needs to be degraded to prevent overdose to the brain tissue. Also if the drug cannot pass back through the blood–brain barrier, it compounds the issues of dosage and intense monitoring would be required. For this to be effective there must be a mechanism for the removal of the active form of the drug from the brain tissue.
=== Russia-Ukraine conflict === Following Russia's invasion of Ukraine in 2022, Teva Pharmaceuticals faced criticism for continuing its operations in Russia despite international sanctions. While the company committed to stopping new investments, its focus on ensuring an uninterrupted supply of medicines has raised ethical concerns, with critics arguing that Teva's presence weakens the impact of sanctions aimed at pressuring Russia economically.
=== Lactation === Prolactin is the primary lactogenic hormone. It drives mammary gland development (mammogenesis), milk synthesis (lactogenesis), and maintenance of milk production. PRLR-knockout mice show absent mammary development. During pregnancy, high estrogen and progesterone promote ductal and lobuloalveolar growth but suppress milk secretion; withdrawal of these steroids at parturition permits prolactin-driven lactogenesis. Suckling activates a neuroendocrine reflex: afferent signals from mechanoreceptors inhibit TIDA dopamine release (raising prolactin) while simultaneously triggering oxytocin release for the milk ejection reflex.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.
No. Dihexa shares a conceptual link to angiotensin IV but has different structural features. Those changes are intended to modify its behavior in biological systems.
It often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. Synonyms and CAS listings vary, so cross-checking identifiers is necessary.
Typical storage is at -20 °C in a desiccated container protected from light. Repeated freeze-thaw cycles are usually minimized to reduce degradation. Specific conditions should follow the supplier’s documentation.